Caregen Co. Ltd
Caregen Co. Ltd is a South Korean KOSDAQ-listed biotech founded in 2001 that develops and commercializes biomimetic peptide-based products across functional food supplements, Class III medical devices, cosmeceuticals, and ophthalmic pharmaceuticals, serving global B2B distribution partners and licensing counterparties through a single integrated peptide platform.
- Company typePublic
- Founded2001
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Caregen Co. Ltd does
Caregen Co. Ltd is a South Korean KOSDAQ-listed biotechnology company founded in 2001 that develops, manufactures, and commercializes biomimetic (biologically inspired) peptide-based solutions across four product verticals: functional food supplements targeting metabolic health, body fat, blood sugar/cholesterol, and sarcopenia; Class III CE-certified medical devices including dermal fillers, hair fillers, body fillers, and arthritis injectables for the medical aesthetic market; cosmeceuticals covering skin, scalp, hair, and inner beauty; and pharmaceuticals, most notably CG-P5, a peptide eye-drop treatment for macular degeneration that has completed US FDA Phase 1 clinical trials, and CG-T1 for dry eye disease with additional trials planned. The company operates from five physical sites in Korea — a Seoul headquarters, an Anyang-si peptide R&D center and Creative Village, a Gunpo-si Cosmetic Research Institute and Factory 1, and a Hwaseong-si Peptide Foundry — providing vertical integration from peptide discovery through manufacturing.
The core of the business is a single biomimetic peptide technology platform that Caregen applies through multiple delivery formats and application designs rather than running separate R&D programs per vertical. This horizontal platform structure is intended to allow the same mechanistic peptide insights to inform ingredients, medical devices, cosmeceuticals, and ophthalmic drug candidates. Caregen monetizes the platform through direct sales of finished products, global distribution partner networks, and licensing programs targeting food supplements, medical devices, cosmeceuticals, and pharmaceutical applications. The company's go-to-market combines B2B distribution partnerships, presence at major international exhibitions across health, medical, beauty, and pharmaceutical sectors, and organic social channels (Instagram, Facebook, YouTube, Naver blog) for brand presence.
Revenue is generated across hardware sales (food supplements, medical devices, cosmeceuticals) and licensing/royalty streams (pharmaceutical assets and platform licensing). Specific pricing, contract structures, and revenue figures are not publicly disclosed. Customers are not named in the available data, and the company sells into B2B distribution partners and licensing counterparties rather than directly identified end accounts. No acquisitions, fundraising rounds, or leadership changes are disclosed in the source material, and Caregen appears to operate as an independent, publicly traded Korean biotech with no identified parent company.
Caregen Co. Ltd firmographics
Firmographics- Name
- Caregen Co. Ltd
- Legal name
- Caregen Co. Ltd
- Website
- https://caregen.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Caregen Co. Ltd is a South Korean KOSDAQ-listed biotech founded in 2001 that develops and commercializes biomimetic peptide-based products across functional food supplements, Class III medical devices, cosmeceuticals, and ophthalmic pharmaceuticals, serving global B2B distribution partners and licensing counterparties through a single integrated peptide platform.
- Ownership category
- akta.pro rank
Caregen Co. Ltd industry classification
Industry- Product category
- Biotechnology — Biomimetic Peptide Ingredients and Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industries
- Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine) (AFAJAKAG), Protein Hydrolysates & Peptides (Enzymatic Hydrolysates, Bioactive Peptides) (AFAJAHAI), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Dermatology Specialty Pharmaceuticals (HLAIACAL)
Keywords
Where Caregen Co. Ltd is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices4 records
Markets served
Caregen Co. Ltd business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
Revenue model
- Functional Food Supplements: Peptide-based functional healthcare solutions for metabolic health, body fat management, blood sugar-cholesterol management, and sarcopenia response across life care segments.
- Medical Devices: Class III medical devices including dermal fillers, hair fillers, body fillers for medical aesthetic markets, and arthritis injectables utilizing biomimetic peptide technology.
- Cosmeceuticals: Functional peptide-based solutions covering skin, scalp, hair, and inner beauty categories with integrated beauty solutions.
- Pharmaceuticals - Licensing: Peptide drug development including CG-P5 for macular degeneration (FDA Phase 1 completed) and CG-T1 for dry eye, targeting non-injection user-friendly treatments with potential licensing revenue.
- Partnership & Licensing: Global partnership and licensing programs for peptide platform technology and applications across food supplements, medical devices, cosmeceuticals, and pharmaceuticals sectors.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Caregen Co. Ltd product offering
Product offeringCore offering
Caregen researches biological signaling mechanisms and develops biomimetic peptide-based solutions applied across four product categories: functional food supplements for metabolic health and body composition, Class III medical devices (dermal fillers, hair fillers, body fillers, and arthritis injectables), cosmeceuticals for skin, scalp, hair, and inner beauty, and peptide pharmaceuticals (CG-P5 for macular degeneration in eye drop form and CG-T1 for dry eye disease). The company operates its own peptide R&D centers and a dedicated Peptide Foundry for high-purity peptide manufacturing, and commercializes its platform through global distribution networks and partnership and licensing programs.
Product overview
Caregen Co. Ltd operates as a biopharmaceutical company built around a single unified peptide technology platform that drives multiple product lines. The core platform consists of biomimetic peptide research and development capabilities, which Caregen applies across four distinct business segments: functional food supplements (metabolic health and body fat management), medical devices (Class III CE-certified dermal fillers, hair fillers, body fillers, and arthritis injections), cosmeceuticals (skin, scalp, and inner beauty solutions), and pharmaceuticals (CG-P5 for macular degeneration with FDA Phase 1 completion as an eye drop formulation, and CG-T1 for dry eye disease). The pharmaceutical products represent user-friendly, non-injection alternatives developed through the same peptide technology foundation.
Differentiator
Problem solved
Functional benefit
Products and services
- CG-P5 Macular Degeneration Treatment Peptide-based ophthalmic drug candidate for macular degeneration formulated as an eye drop (rather than an intravitreal injection), with US FDA Phase 1 clinical trial completed; targeted at pharmaceutical partners and ultimately patients with macular degeneration.
- CG-T1 Dry Eye Treatment Peptide-based therapeutic for dry eye disease, in development with additional clinical trials planned; targets pharmaceutical partners pursuing patient-friendly, non-injection ophthalmic treatments.
- Dermal Fillers (더말필러) Class III peptide-combination dermal filler medical device, CE certified under European standards, sold into the medical aesthetic market for facial volume and wrinkle indications.
- Hair Fillers (헤어필러) Class III peptide-based hair filler medical device for hair restoration and scalp treatment applications, CE certified and sold into the medical aesthetic market.
- Body Fillers (바디필러) Class III biomimetic peptide body filler medical device for body contouring and aesthetic treatments, positioned within the medical aesthetic device market.
- Arthritis Injection (관절염 주사제) Peptide-based injectable medical device for arthritis treatment, used to expand Caregen's biomimetic peptide technology into the orthopedic and therapeutic medical device market.
- Functional Food Supplements Peptide-based functional food and dietary supplement product line covering metabolic health, body fat management, blood sugar and cholesterol management, and sarcopenia response, sold to functional food brands and manufacturers as ingredients or finished products.
- Cosmeceutical Solutions Integrated peptide-based cosmeceutical product line covering skin care, scalp care, hair care, and inner beauty applications, supplied to cosmetic and personal care brands and distribution partners globally.
Quantifiable outcome
- CG-P5 FDA Phase 1 clinical trial completed for macular degeneration treatment
- +2 more outcomes
Companies that use Caregen Co. Ltd
Customer profileSegments4 records
Ideal customer profiles4 records
Caregen Co. Ltd technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Caregen Co. Ltd partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Global Distribution PartnerscoreCaregen operates global distribution networks to deliver its peptide-based solutions across food supplements, medical devices, cosmeceuticals, and pharmaceuticals to international markets. The company connects its technology and products directly to global markets through these distribution partnerships.
- Partnership and Licensing PartnerscoreCaregen offers partnership and licensing programs covering overview, types, value propositions, and global distribution aspects. Partners can access Caregen's peptide platform technology for applications in health functional foods, medical devices, cosmeceuticals, and pharmaceutical development including drug candidates like CG-P5.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Caregen Co. Ltd competitors and assessment
Company assessmentMarket position
Strengths3 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Caregen Co. Ltd social profiles
Digital presenceCaregen Co. Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Caregen Co. Ltd leadership team
Management profileNumber of profiles
Caregen Co. Ltd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Caregen Co. Ltd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Caregen Co. Ltd
What does Caregen Co. Ltd do?
Caregen researches biological signaling mechanisms and develops biomimetic peptide-based solutions applied across four product categories: functional food supplements for metabolic health and body composition, Class III medical devices (dermal fillers, hair fillers, body fillers, and arthritis injectables), cosmeceuticals for skin, scalp, hair, and inner beauty, and peptide pharmaceuticals (CG-P5 for macular degeneration in eye drop form and CG-T1 for dry eye disease). The company operates its own peptide R&D centers and a dedicated Peptide Foundry for high-purity peptide manufacturing, and commercializes its platform through global distribution networks and partnership and licensing programs.
Is Caregen Co. Ltd a public or private company?
Caregen Co. Ltd is a public company. It is classified as public and is currently operating.
When was Caregen Co. Ltd founded?
Caregen Co. Ltd was founded in 2001. It employs 11 to 50 people.
Where is Caregen Co. Ltd based?
Caregen Co. Ltd is headquartered in Seoul, South Korea, in the Asia region.
How does Caregen Co. Ltd make money?
Five revenue lines are on record. Functional Food Supplements are the primary driver. The others are medical Devices, cosmeceuticals, pharmaceuticals - Licensing and partnership & Licensing.
Does Caregen Co. Ltd have an API?
No public API is recorded for Caregen Co. Ltd.
What industry is Caregen Co. Ltd in?
Caregen Co. Ltd's product category is Biotechnology — Biomimetic Peptide Ingredients and Products. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of AFAJAKAG, Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine). Its NAICS code is 325414 and its SIC code is 2836.